Abstract
Patients with systemic mastocytosis are rare, constitute a heterogenous clinical entity and some may not require treatment until long after diagnosis. However, most patients who present with disabling symptoms, organ involvement and fulfill B or C findings as outlined in the 2008 WHO classification need treatment. This review on interferon treatment in systemic mastocytosis documents an effect of this biological agent in some patients with mastocytosis. However, the place of interferon-α, as mono- or combination therapy, in the treatment algorithm may only be definitely established in multicenter studies, which are based on the principles of controlled clinical trials.
Keywords: Mast cells, mastocytosis, interferon, classification, treatment, review
Current Drug Targets
Title: Interferon-α Treatment in Systemic Mastocytosis
Volume: 12 Issue: 3
Author(s): Ole Weis Bjerrum
Affiliation:
Keywords: Mast cells, mastocytosis, interferon, classification, treatment, review
Abstract: Patients with systemic mastocytosis are rare, constitute a heterogenous clinical entity and some may not require treatment until long after diagnosis. However, most patients who present with disabling symptoms, organ involvement and fulfill B or C findings as outlined in the 2008 WHO classification need treatment. This review on interferon treatment in systemic mastocytosis documents an effect of this biological agent in some patients with mastocytosis. However, the place of interferon-α, as mono- or combination therapy, in the treatment algorithm may only be definitely established in multicenter studies, which are based on the principles of controlled clinical trials.
Export Options
About this article
Cite this article as:
Weis Bjerrum Ole, Interferon-α Treatment in Systemic Mastocytosis, Current Drug Targets 2011; 12 (3) . https://dx.doi.org/10.2174/138945011794815293
DOI https://dx.doi.org/10.2174/138945011794815293 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Regulation and Function of DNA and Histone Methylations
Current Pharmaceutical Design Design, Preparation and Characterization of Modular Squalene-based Nanosystems for Controlled Drug Release
Current Topics in Medicinal Chemistry Carbon Nanotubes: Classification, Method of Preparation and Pharmaceutical Application
Current Drug Delivery Dendritoma Vaccine for Cancer: A Hopeful Approach
Current Cancer Therapy Reviews In Vitro Models of Human T Cell Development: Dishing Out Progenitor T Cells
Current Immunology Reviews (Discontinued) A Review on the Synthetic Approach of Marinopyrroles: A Natural Antitumor Agent from the Ocean
Letters in Organic Chemistry Future Prospect of RNA Interference for Cancer Therapies
Current Drug Targets Plant Ribonucleases and Nucleases as Antiproliferative Agens Targeting Human Tumors Growing in Mice
Recent Patents on DNA & Gene Sequences Development of Radicicol Analogues
Current Cancer Drug Targets Computational Insights for the Discovery of Non-ATP Competitive Inhibitors of MAP Kinases
Current Pharmaceutical Design Ricin and Saporin: Plant Enzymes for the Research and the Clinics
Current Chemical Biology Old Drugs-Current Perspectives
Current Pharmacogenomics Forodesine (BCX-1777, Immucillin H) - A New Purine Nucleoside Analogue: Mechanism of Action and Potential Clinical Application
Mini-Reviews in Medicinal Chemistry Merkel Cell Carcinoma: Epidemiology, Clinical Presentations, Histology, Polyomavirus Involvement, and Management
Current Cancer Therapy Reviews Genes Associated with Epithelial-Mesenchymal Transition: Possible Therapeutic Targets in Ductal Pancreatic Adenocarcinoma?
Anti-Cancer Agents in Medicinal Chemistry Dietary Phytochemicals in Chemoprevention of Cancer: An Update
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) CFTR and MDR: ABC Transporters with Homologous Structure but Divergent Function
Current Genomics Implications of Somatic Mutations in the AML1/RUNX1 Gene in Myelodysplastic Syndrome (MDS): Future Molecular Therapeutic Directions for MDS
Current Cancer Drug Targets Surface Plasmon Resonance Imaging (SPRI) Sensor for Cystatin Determination Based on Immobilized Papain
Protein & Peptide Letters Evolutionary Advantage and Molecular Modes of Action of Multi-Component Mixtures Used in Phytomedicine
Current Drug Metabolism